RT Journal Article
SR Electronic
T1 Genomic surveillance of SARS-CoV-2 in the state of Paraná, Southern Brazil, reveals the cocirculation of the VOC P.1, P.1-like-II lineage and a P.1 cluster harboring the S:E661D mutation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.14.21260508
DO 10.1101/2021.07.14.21260508
A1 Mauro de Medeiros Oliveira
A1 Michelle Orane Schemberger
A1 Andreia Akemi Suzukawa
A1 Irina Nastassja Riediger
A1 Maria do Carmo Debur
A1 Guilherme Becker
A1 Paola Cristina Resende
A1 Tiago Gräf
A1 Eduardo Balsanelli
A1 Valter Antônio de Baura
A1 Emanuel Maltempi de Souza
A1 Fábio de Oliveira Pedrosa
A1 Lysangela Ronalte Alves
A1 Lucas Blanes
A1 Sheila Cristina Nardeli
A1 Alessandra De Melo Aguiar
A1 Letusa Albrecht
A1 Dalila Zanette
A1 Andréa Rodrigues Ávila
A1 Luis Gustavo Morello
A1 Fabricio Klerynton Marchini
A1 Hellen Geremias dos Santos
A1 Fabio Passetti
A1 Bruno Dallagiovanna
A1 Helisson Faoro
YR 2021
UL http://medrxiv.org/content/early/2021/07/15/2021.07.14.21260508.abstract
AB We report a genomic surveillance of SARS-CoV-2 lineages circulating in Paraná, Southern Brazil, from March 2020 to April 2021. Our analysis, based on 333 genomes, revealed that the first variants detected in the state of Paraná in March 2020 were the B.1.1.33 and B.1.1.28 variants. The variants B.1.1.28 and B.1.1.33 were predominant throughout 2020 until the introduction of the variant P.2 in August 2020 and a variant of concern (VOC), P.1, in January 2021. Phylogenetic analyses of the SARS-CoV-2 genomes that were previously classified as the VOC P.1 lineage by PANGO showed that some genomes from February to April 2021 branched in a monophyletic clade and that these samples grouped together with genomes recently described with the lineage P.1-like-II. An extended phylogenetic analysis, including SARS-CoV-2 genomes from all over Brazil, showed that the P.1-like-II lineage appears at a high frequency in the southern region of the country. The P.1-like-II lineage genomes share some, but not all, defining mutations of the VOC P.1. For instance, it has the previously described ORF1a:D2980H and N:P383 L unique mutations and the newly detected ORF1a:P1213 L and ORF1b:K2340N mutations. Additionally, a new mutation (E661D) in the spike (S) protein has been identified in nearly 10% of the genomes classified as the VOC P.1 from Paraná in March and April 2021. We also report the identification of the S:W152C mutation in one genome from Paraná, classified as the N.10 variant. Finally, we analyzed the correlation between the lineage and the P.1 variant frequency, age group (patients younger or older than 60 years old) and the clinical data of 86 cases from the state of Paraná. This analysis does not support an association between the P.1 variant prevalence and COVID-19 severity or age strata. Our results provided a reliable picture of the evolution of the SARS-CoV-2 pandemic in the state of Paraná characterized by the dominance of the P.1 strain, as well as a high frequencies of the P.1-like-II lineage and the S:E661D mutations. Epidemiological and genomic surveillance efforts should be continued to unveil the biological relevance of the novel mutations detected in the VOC P.1 in Paraná.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study was approved by the Hospital do Trabalhador/SES/PR Ethics Committee: CAAE 31650020.5.0000.5225.Funding StatementPrograma de Excelência em Pesquisa Conselho Nacional de Pesquisa/Instituto Carlos Chagas (PROEP CNPq/ICC Grant n. 422329/2019-9; 442339/2019-4; 442376/2019-7; 442421/2019-2; 442338/2019-8; 442375/2019-0; 442381/2019-0. Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) Call - Preventing and Combating Outbreaks, Endemics, Epidemics and Pandemics: Grant n. 88887.504690/2020-00. Inova Fiocruz: Grant n. VPPIS-001-FIO-18-52. CNPq/Ministério da Ciência, Tecnologia e Inovação/Ministério da Saúde (MS/FNDCT/SCTIE/Decit) Grant n. 403276/2020-9.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Hospital do Trabalhador/SES/PR Ethics Committee: CAAE 31650020.5.0000.5225.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSupplementary figures Figure S1: SARS-CoV-2 variants identified at Paraná state in April 2021. Figure S2: Distribution of SARS-CoV-2 variants identified in April 2021, according to macro-regions of Paraná state. Figure S3: SARS-CoV-2 variants identified at Paraná state in April 2021, by age group. Figure S4: SARS-CoV-2 variants identified at Paraná state in April 2021, by clinical severity at the moment of sample collection (LAC: mild cases; LACEN: severe cases). Supplementary list List S1: GISAID accession numbers of 245 news genomes from Paraná produced by the Fiocruz COVID-19 Genomic Surveillance Network. Supplementary tables Table S1: Non-synonymous mutations described for VOIs N.10-PR, N.10-MA and B.1.429. Table S2: Non-synonymous mutations described for P.1-like-II. Supplementary appendix Appendix S1: GISAID acknowledgment. https://github.com/mauromedeirosoliveira/Fiocruz-ICC